Last week Rosetta Inpharmatics and Agilent Technologies signed three Max Planck Institutes to act as European demonstration sites for the Rosetta Resolver gene expression data analysis system and Agilent’s recently launched DNA Microarray Scanner.
Under the terms of the agreement, researchers at the Max Planck Institute for Molecular Genetics, the MPI for Infection Biology (both in Berlin, Germany), and the MPI for Molecular Plant Physiology (in Golm, Germany) will have full access to the use of the products, while the facilities will also serve as locations for prospective customers to test the equipment.
Further terms of the agreement were not disclosed.
Rosetta Inpharmatics of Kirkland, Wash., has also launched a satellite customer service operation in Europe, housed at Agilent Technologies’ facility in Amsterdam, The Netherlands. Rosetta spokeswoman Myra Ozaeta said there is currently one manager at the facility who is charged with opening the office and serving as a technical resource for the Agilent sales staff there. While there are no specific plans in place yet for expansion of the European operation, Ozaeta noted that “our goal is to grow the market there.”
Currently, Rosetta’s only customer outside the US is GlaxoSmithKline, based in the UK. Ozaeta said the Max Planck demonstration sites and the customer service operation are important steps toward increasing the company’s exposure in the European market.
Agilent spokesman Doug Forsyth said that the Max Planck Institute’s reputation as a top-level research facility “gives a lot of cachet” to the placement of the companies’ technologies there.
Agilent, which released the automated DNA Microarray Scanner at the end of June, holds exclusive distribution rights to the Rosetta Resolver system.